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Since 2004, the red fluorescent dye Sulforhodamine 101 (SR101) has been boosting
the functional analysis of astrocytes in a functional environment in an unprecedented
way. However, two major limitations have been challenging the usefulness of this tool
for cellular imaging: (i) SR101 is not as specific for astrocytes as previously reported;
and (ii) discoveries of severe excitatory side effects of SR101 are bearing the risk of
unwanted alteration of the system of interest. In this article, we summarize the current
knowledge about SR101-labeling protocols and discuss the problems that arise from
varying of the staining protocols. Furthermore, we provide a testable hypothesis for the
observed hyper-excitability that can be observed when using SR101.
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The red fluorescent dye, Sulforhodamine 101 (SR101), is a rather old tool for life scientists.
First used for flow cytometry already in 1978 (Stöhr et al., 1978), it later appeared to be helpful
for labeling of active synapses (Lichtman et al., 1985), as well as neurons and astrocytes in
intact preparations (Cina and Hochman, 2000). The description of ‘‘Sulforhodamine 101 as
a specific marker of astroglia in the neocortex in vivo’’ in 2004 (Nimmerjahn et al., 2004)
boosted the research on astroglial cells. However, many aspects, including the ultimate mechanism
of SR101 uptake into astrocytes remained unknown and, furthermore, the method has been
challenged by a lack of cell type specificity and reports of excitatory side effects. Since the
method is used by a still growing number of research groups, we summarize the available
information of SR101-staining and its limitation with respect to cell specificity from the current
literature and discuss the excitatory side effect in the context of recent publications and our own
experimental data, which point towards a role of neurosteroids in the generation of SR101-induced
hyper-excitability.
FLUORESCENT LABELING PROTOCOL AND TYPE OF LABELING
Different staining protocols have been used to label astrocytes. For in vivo imaging, SR101 was
applied topically at concentrations of 250 nM to 300 µM or by bolus injection (Nimmerjahn
et al., 2004; Nimmerjahn and Helmchen, 2012). Additionally, SR101 injection over the
tail vein (10 mg/ml) has been reported to be successful (Appaix et al., 2012). Acute brain
slices are usually incubated in carbonated extracellular solution containing 0.5–1 µM
SR101 for 20–30 min and 34–37◦C. Following this, excess dye is removed over a period
of 10–30 min using different protocols that were described earlier (Kafitz et al., 2008;
Meier et al., 2008; Kantor et al., 2012; Schnell et al., 2012, 2015; Augustin et al., 2016;
Hagos and Hülsmann, 2016). These protocols lead to labeling of cell somata and proximal
processes of astrocytes. The fine distal processes of astrocytes as revealed e.g., by transgenic
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expression of fluorescent protein, are often difficult to identify
by SR101 (see Figure 1A). If the staining is weaker (e.g., in the
brainstem), proximal processes appear unlabeled.
THE PROBLEM OF CELL TYPE
SPECIFICITY
SR101 became extremely important for the study of astrocytes
after the publication by Nimmerjahn et al. (2004). For
the relatively novel field of glia-physiology that was always
depending on genetically engineered mice to label the cell
type of interest for physiological studies with a fluorescent
protein (Nolte et al., 2001) or, before these animals became
available, by post hoc immunohistochemical counterstaining of
dye-filled cells with antibodies against astroglial marker proteins,
e.g., GFAP (Konietzko and Müller, 1994), SR101 soon became
indispensable.
The protocol of SR101 labeling was cheap and easily
established in a laboratory, and could be used in vivo as
well as in slice preparations from rostral brain region (Kafitz
et al., 2008; see Figure 1A as an example). SR101 could be
used to counterstain astrocytes when analyzing other cell types
(Nimmerjahn et al., 2005) or for identification of astrocytes when
analyzing electrophysiological properties of cells (Du et al., 2016)
or together with calcium imaging of astrocytes (Pirttimaki and
Parri, 2012). Furthermore, it initially appeared not to alter the
physiological properties of brain cells.
First problems with uncritical usage of SR101 were revealed
in hypoxic conditions when neuronal hemichannels are opened
and SR101 can enter neurons (Thompson et al., 2006). Moreover,
SR101 does not label astrocytes in brainstem slices as strong and
specific as in the hippocampus or cortex (Schnell et al., 2015).
This lighter staining intensity, together with some dye entering
neurons makes interpretation of SR101 labeling unreliable in
these brain regions (Schnell et al., 2012, 2015).
Additionally, it became evident that it was overlooked
that SR101 can diffuse via gap junctions from astrocytes to
oligodendrocytes, thereby impairing a reliable identification of
astrocytes (Wasseff and Scherer, 2011; Hill and Grutzendler,
2014; Hagos and Hülsmann, 2016). Since gap junctions
connect oligodendrocytes and astrocytes in many brain regions
(Orthmann-Murphy et al., 2008; Griemsmann et al., 2015), it
cannot be assumed that all SR101-labeled cells are astrocytes.
In our hands, approximately 45% of SR101-positive cells did
not express the fluorescent protein in the hippocampus of
TgN (hGFAP-EGFP) mice (Schnell et al., 2012). Indeed, over
30% of SR101-labeled cortical cell were oligodendrocytes and,
moreover, all mature oligodendrocytes in PLPcreER: mT/mG
transgenic mice were reported to be SR101-labeled in vivo
(Hill and Grutzendler, 2014).
WHAT IS THE UPTAKE MECHANISM
OF SR101-LABELING?
The accumulation of SR101 in astrocytes to a higher
concentration compared to the extracellular solution
indicated an active transport of SR101 into astrocytes in
FIGURE 1 | (A) SR101-labeling of astrocytes identified by transgenic
expression of EGFP (green) using TgN(hGFAP-EGFP)GFEC-Fki; (Nolte et al.,
2001). Incubation of the brain slice with 1 µM SR101 for 20 min at 34◦C
followed 10 min of de-staining in artificial cerebrospinal fluid (aCSF) reveals
that also some cells are nicely labeled by SR101 but do not express the
astrocyte marker (asterisk). Note that the SR101 fluorescence is reaching the
end feet of the astrocytes (fine arrow), but is weak in the distal processes of
the astrocytes. (B) SR101-staining of oligodendrocytes that were identified by
transgenic expression of EGFP using TgN(PLP-GFP) mice (Spassky et al.,
2001). Slices were incubated in 1 µM SR101 for 140 min at 34◦C followed
10 min of de-staining in aCSF. This method reveals that also cells from the
oligodendrocyte linage (open arrows) are labeled by SR101. The intensity of
SR101 is weaker as compared to neighboring GFP-negative cells. Image
acquisition using 2-Photon excitation microscopy was described previously for
astrocytes (Schnell et al., 2012) and oligodendrocytes (Hagos and Hülsmann,
2016). Pictures are surface mode projections of 100 µm image stacks
generated by Imaris software (Bitplane).
contrast to diffusion-based mechanism via gap junctions or
hemichannels (Schnell et al., 2012). The pharmacological
profile of SR101 pointed towards an organic anion transporting
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TABLE 1 | The table summarizes labeling procedures that have been found to be not specific for astrocytes.
Protocol Cell types labeled Reference Excitatory side effects reported
Slice; 10–140 min incubation at 34◦C,
0.5–1 µM SR101
Astrocytes and
oligodendrocytes
Wasseff and Scherer (2011),
Hagos and Hülsmann (2016)
Long-term negative shift of AP threshold,
LTP; ≥1 µM SR101 for 10 min;
(Kang et al., 2010);
LTP ≥25 µM SR101 for 10 min SR101
(Fink et al., 2012)
Slice; incubation at RT (20–23◦C),
165 µM SR101
Neurons Kantor et al. (2012), this article –
Slice, incubation and OGD at RT,
100 µM SR101 Neurons Thompson et al. (2006) –
In vivo; 100 µL intravenously 5 mM
SR101in PBS Astrocyte and
oligodendrocytes
Hill and Grutzendler (2014) –
In vivo; topically to cortical surface
for 5–10 min, 50 µM SR101
Astrocytes and
oligodendrocytes
Hill and Grutzendler (2014) Seizure-like activity,
≥100 µM SR101 for 10 min
(Rasmussen et al., 2016)
RT, room temperature; OGD, oxygen glucose deprivation; PBS, Phosphate buffered saline; LTP, Long term potentiation.
polypeptide (Schnell et al., 2012) and subsequent transcriptome
analysis revealed region-specific differences in mRNA levels
of the putative SR101 transporter, between brainstem and
cortex/hippocampus, allowing the identification of the organic
anion transporting polypeptide OATP1C1 (OATP14, OATPF,
Slco1c1) as the responsible transporter for SR101 uptake
into astrocytes (Schnell et al., 2015). The blockade of SR101-
labeling by the unspecific gap junction blocker carbenoxolone
(CBX) previously led to the conclusion that gap junctions
are involved in the labeling of astrocytes with SR101. This is
certainly true for the distribution of SR101 within the astroglial
networks, but the complete blockade of SR101-labeling is
probably caused by the blockade of the OATP1C1 by CBX
(Nishimura et al., 2007; Schnell et al., 2012). Further evidence
for this was the reduction of astroglial SR101-labeling by the
organic anions MK-571 and Probenecid, which are known
substrates of OATPs and would compete with SR101 for uptake
via the OATP1C1 (Schnell et al., 2012). The ultimate proof
comes from the blockade of SR101 labeling by the natural
substrate of OATP1C1 levothyroxine (T4) and the absence
of astrocytic SR101 labeling in OATP1C1-deficient mice
(Schnell et al., 2015).
WHY ASTROCYTES ARE PREFERENTIAL
LABELED?
Although OATP1C1 expression is a necessity for SR101 labeling
of astrocytes (Schnell et al., 2015) and also oligodendrocytes
(Hagos and Hülsmann, 2016; see also Figure 1B), its expression
in astrocytes is not sufficient to explain the preferential labeling
of astrocytes (and secondarily oligodendrocytes). At first, other
cell types, such as endothelial cells express OATP1C1 (Lang et al.,
2011; Ridder et al., 2011), and also neurons synthetize high levels
of Oatp1c1 mRNA (Cahoy et al., 2008). However, the functional
expression levels of OATP1C1 protein in neurons are uncertain
(Lang et al., 2011; Ridder et al., 2011). Interestingly, we found
that neurons in the brainstem are loaded with SR101 during
the staining procedure, leading to even higher fluorescence
intensities in neurons as compared to neighboring astrocytes
and the extracellular solution (Schnell et al., 2012). Yet, neurons
are de-staining very quickly. Since this de-staining is blocked
by MK-571, a blocker of ABC-transporters (Schnell et al.,
2012), an additional differential expression of a yet unidentified
transporter that mediates the extrusion of SR101 from neurons
but not from astrocytes is required to explain these results.
Since the time course of astrocyte labeling was slower as
compared to neurons (Schnell et al., 2012), we also have to
assume a different labeling process in neurons. Indeed, we found
that SR101 labeling of superficial hippocampal neurons is still
possible in the OATP1C1 knockout mouse or after application of
levothyroxine (T4), a natural OATP1C1 substrate (Schnell et al.,
2015). If this neuronal labeling was, as initially assumed, due
to hypoxia-mediated hemichannels opening (Thompson et al.,
2006), it should be prevented by application of a gap junction
blocker. Although the intensity is slightly reduced, neurons in
OATP1C1-deficent mice are still SR101-labeled after application
of 100 µM CBX (Figures 2A,B,E). High concentration of
SR101 (165 µM) applied at room temperature have been shown
to preferentially label neurons in the hippocampus and locus
coeruleus (Kantor et al., 2012). When testing this concentration
in OATP1C1-deficient mice in the presence of CBX, we still
observed neuronal labeling (Figures 2C,D), pointing towards
an independent unknown SR101-uptake mechanism that is not
present in astrocytes.
EXCITATORY SIDE EFFECTS OF THE
LABELING
It seems obvious that a substance that interferes with a
multi-specific transporter in the brain will cause side effects
if applied at high concentrations. Indeed, recent reports of
increased neuronal excitability challenged the usefulness of
SR101 for functional analysis (Kang et al., 2010). Even at a
concentration as low as 1 µM, SR101 increased the excitability
in slices, including induction of LTP that outlasted the
application time (Kang et al., 2010). Others reported similar
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FIGURE 2 | Neuronal labeling in the CA1 region of the hippocampus
by SR101 does not require OATP1C1. (A) Labeling of slices from Oatp1c1
knock out mice (Mayerl et al., 2012) using 1 µM SR101 for 20 min at 34◦C
followed 10 min of de-staining in aCSF (Schnell et al., 2012). (B) Same
protocol except that 100 µM of carbenoxolone (CBX) was added during the
staining procedure. Note that labeling of neurons was not reduced by CBX. In
(C,D) the staining procedure was altered and 165 µM SR101 was applied at
room temperature (Kantor et al., 2012). This protocol leads to a much brighter
staining of neurons (see lookup table that was used for all four panels) but not
to a staining of astrocyte-like cells. Again application of 100 µM CBX did not
block the neuronal labeling. (E) Statistical analysis of the fluorescence intensity
of neurons. Threshold based pixel analysis using ImageJ software. The
asterisks indicated significance between 165 µM and 1 µM SR101
treatments. ANOVA with all pairwise multiple comparison procedures
(Holm-Sidak method; p < 0.05; n = 3 mice) using SigmaPlot software.
effects only at higher SR101 concentration (Fink et al., 2012).
In vivo, epileptic activity could be induced by intra-hippocampal
injection of small volumes of 10 µM SR101 (Kang et al.,
2010) or topical application of 100 µM (Rasmussen et al.,
2016). The mechanism of SR101-induced hyper-excitability
remains to be determined, though SR101-induced LTP was
due to amplification of NMDA-receptor mediated currents
(Kang et al., 2010).
The fact that SR101 uses OATP1C1, a thyroid hormone
transporter (Sugiyama et al., 2003; Friesema et al., 2005), for
entering the astrocytes, does not offer a plausible explanation for
the changes of excitability alone. An increase of the extracellular
levothyroxine (T4) or triiodothyronine (T3) levels induced by the
competition of SR101 with their uptake transporter is expected to
reduce neural excitability rather than causing hyper-excitability
(Losi et al., 2008; Cao et al., 2011).
On the other hand, sulfated steroids (DHEAS, Estron-3-
sulfate (Schnell et al., 2012), and allopregnanolone sulfate (3α,
5α-tetrahydroprogesterone sulfate; 3α, 5α-THP sulfate) blocked
the uptake of SR101 into hippocampal and cortical astrocytes
(Figure 3). We postulate that the competition of SR101 with the
natural uptake of sulfated neurosteroids can change neuronal
activity by enhancement of NMDA-receptors and inhibition of
GABAA-receptors (Gibbs and Farb, 2000). Since neurosteroids
levels do vary in the brain depending on different factors like
FIGURE 3 | Effects of neurosteroids on SR101 uptake in the
hippocampus. (A) Astroglial EGFP-fluorescence (green) and
SR101-fluorescence (red) in the hippocampus after a staining in control
conditions (1 µM SR101 for 20 min at 34◦C). (B) Reduced SR101-labeling of
hippocampal astrocytes when the neurosteroid allopregnanolone sulfate
(APAS, 100 µM) was included in the staining solution. Both figures show
maximum intensity projection 51 stacks (2 µm distance). (C–F) Images from
single layer for EGFP (C,D) and SR101 (E,F). Note the reduction of the
intensity of SR101 after application of APAS (F). (G–I) Statistical analysis:
(G) The reduction of the SR101-intensity by 100 µM APAS is significant
(Mann-Whitney Rank Sum Test; p = 0.032; n = 5 slices; 3 mice).
(H) Additionally the number of SR101 positive cells than can be identified after
APAS is reduced (t-Test; p = 0.040). (I) The APAS-induced reduction of
SR101 intensity in EGFP-positive cells and EGFP-negative SR101 labeled
cells is not different (Mann-Whitney Rank Sum Test; p = 0.548). Asterisks in
(G,H) indicate significance (p < 0.05).
stress and estrus (Paul and Purdy, 1992) it is difficult to predict
if changes in excitability are induced by SR101 at a certain
experimental condition. On the other hand, it is tempting to
speculate that such variation in neurosteroids levels can explain
that side effects have been seen by some groups but not by
others.
CONCLUSION
Given the limitations of the SR101 as mentioned above and
summarized in Table 1, it is necessary to give a statement
of caution. The use of SR101, without being aware of the
caveats regarding cell type specificity and possible side
effects, might affect the validity of research. Therefore,
researchers should be encouraged to employ additional
measures like electrophysiological whole-cell recordings of
SR101-labeled cells and post hoc immunohistochemistry
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to confirm the specificity of SR101 staining in their
experimental setting. To minimize excitatory side effects,
the concentration of SR101 has to be kept as low as possible
or the labeling procedure could be performed after the actual
experiment.
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